Loading provider…
Loading provider…
Neurology Physician in New York, NY
NPI: 1538256615Primary Practice Location
NEW YORK-PRESBYTERIAN HOSPITAL
5141 Broadway, New York, NY
Primary Employer
Weill Medical College of Cornell
med.cornell.edu
HQ Phone
Get MD Michael's Phone NumberMobile
Get MD Michael's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardNY State Medical License
University of California (San Francisco) School of Medicine
Medical School
Until 1992
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 354 | 485 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 269 | 339 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 177 | 177 |
| 4 | 99213Established patient office or other outpatient visit, typically 15 minutes | 41 | 43 |
| 5 | 99443Physician telephone patient service, 21-30 minutes of medical discussion | 22 | 23 |
Detecting Non-cognitive Features of Prodromal Neurodegenerative Diseases.
Authors: Richard Isaacson, Chin Shun Shih
Journal: Curr Aging Sci
Mitochondrial DNA from platelets of sporadic ALS patients restores normal respiratory functions in ρ0 cells
Authors: Carl D. Gajewski, Michael T. Lin, Merit Cudkowicz, M. Flint Beal, Giovanni Manfredi
Publication Date: 2003-02
Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinson's disease.
Authors: David Simon
Journal: Neurobiol Aging
Lead Sponsor: Eli Lilly and Company
Collaborators: Alzheimer's Therapeutic Research Institute
Intervention / Treatment: DRUG: Placebo, DRUG: Solanezumab
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Lebrikizumab
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Lebrikizumab